Oh, what a shocking revelation we have here! After years of research, it turns out that the magical potion known as recombinant human erythropoietin (rHu-EPO) is, well, not so magical for preterm infants when it comes to dodging those pesky packed red blood cell transfusions (pRBCTs). In a thrilling twist of medical practice, some neonatal units in France have been playing a game of ‘Should we, shouldn’t we?’ with rHu-EPO. So, researchers decided to roll up their sleeves and dive into the data from 2018 to 2020 to see if rHu-EPO was the hero we all hoped it would be.

They rounded up a cohort of 257 tiny humans exposed to rHu-EPO and 285 who were not, and guess what they found? For the micro VIPs born before 28 weeks, rHu-EPO didn’t make a difference. It’s like they were saying, “Thanks, but no thanks, we’ll take our chances.” For the slightly older crowd of 28 to 30 weeks, rHu-EPO seemed to play hard to get, with a tease of benefit that wasn’t really there upon closer inspection. And for the ones born after the grand 30-week mark, rHu-EPO was about as useful as a chocolate teapot.

But wait, there’s a plot twist! Early iron supplementation strutted onto the stage, flexing its muscles as the real MVP in this blood transfusion avoidance saga. So, what’s the moral of the story? rHu-EPO might need a time-out to rethink its life choices, while iron supplements take the spotlight. And as for the future of rHu-EPO, let’s just say it’s about as clear as mud. Careful consideration, therapeutic schedule adjustments, and evolving indications for pRBCT are the new buzzwords. Stay tuned for the next episode of ‘As the Medical World Turns’!